Celgene hits endpoint in psoriatic arthritis but misses in rheumatoid
This article was originally published in Scrip
Executive Summary
Celgene said on 12 July that its small-molecule phosphodiesterase 4 (PDE4) inhibitor apremilast showed statistical significance for the primary endpoint of ACR20 in the first of three pivotal Phase III clinical trials in psoriatic arthritis (PsA), but it missed the same endpoint in the first of two Phase II studies in rheumatoid arthritis (RA).